RT/follows do not imply endorsement. Bradley A. Maron, MD Editor-in-Chief, Circulation
Boston, MA
Joined February 2012
- Tweets12.2K
- Following3.8K
- Followers79.2K
- Likes304
Pinned Tweet
For decades, Circulation has guided the field. Now, a new editor continues that legacy while shaping what comes next. We're excited to announce Bradley A. Maron, MD (@bradleymaronmd) as the next Editor-In-Chief.
How does research become real-world impact? Explore the path from scientific discovery to clinical implementation and policy relevance with leaders from @CircAHA.
📅 Nov. 9 | 🕜 8:00-9:15 AM CT | 📍 N228
Add it to your #ScientificSessions26 schedule
Circulation retweeted
Come meet the editors of the AHA Journals today at #ScientificSessions2026, including the @CircAHA team, and hear about the new editorial vision for Circulation.
Sun, Nov 8 | 3:30 PM CT | Engagement Lounge, HQ
Full Details: ahajournals.org/AHASessions
@AHAScience
New CADENCE data show sotatercept improves🔑echocardiographic measures of pulmonary hypertension, providing mechanistic insights into efficacy for patients combined post- and precapillary #pulmonaryhypertension with #HFpEF... ahajrnls.org/4k5bFgS
... a condition with major unmet clinical need
#ScientificSessions26 @AHAScience
ahajournals.org/doi/10.1161/… @RyanJTedfordMD @DNSilvermanMD @rabeaasleh
As #HeartTransplant survival improves, protecting kidney health matters more. A new commentary on #DAPARHT asks how to interpret the effects of dapagliflozin on eGFR in heart transplant recipients. #ScientificSessions26 @AHAScience
ahajrnls.org/4BKxxUV
Dapagliflozin vs placebo in #HeartTransplant recipients: improved the slope of eGFR from 2 weeks to 12 months of treatment. Supports the safety of #SGLT2i in a new population. #ScientificSessions26 @AHAScience
@kevin_damman @KasparBroch
ahajrnls.org/4zbAQlA
What does IRONMET-HFpEF mean for how we treat patients? @FudimMarat & @AndrewPAmbrosy take on the question in a new commentary: an endpoint is not yet an indication. #ScientificSessions26 @AHAScience
ahajrnls.org/4zBepYb
In patients with #HFpEF and iron deficiency, IV ferric derisomaltose improved measures of exercise capacity in the IRONMET-HFpEF trial.
#ScientificSessions26 @AHAScience
@Raj_MalhotraMD @AlvaroDelgadoMD
ahajrnls.org/3XcIFKl
📣 Don't miss this opportunity to connect with leading voices in cardiology!
Join us for a Meet & Greet with @CircAHA Editors on Nov 8 from 3:30-4:15 PM CT in the Engagement Lounge.
Bring your questions and we'll see you there! #ScientificSessions26
Real progress takes real allyship. Join leaders, including EICs of @CircAHA and @JAHA_AHA, for a candid conversation on sponsorship, visibility, and advocacy. #ScientificSessions26
📅 Nov. 8 | 🕜 9:45-11:00 AM CT | 📍 Member Lounge
🚨 From model to medicine: the future of cardiovascular AI.
Join AI investigators & leaders of major journals, including @CircAHA, to discuss the modern evidence lifecycle of AI from development through deployment.
📅 Nov. 8 | 🕗 8-9:15 AM CT |📍N228
#ScientificSessions26
🚨 From model to medicine: the future of cardiovascular AI.
Join AI investigators & leaders of major journals, including @CircAHA, to discuss the modern evidence lifecycle of AI from development through deployment.
📅 Nov. 8 | 🕗 8-9:15 AM CT |📍N228
#ScientificSessions26
Clear target, multiple paths. In an Editor's Note, @DrM_ODonoghue explores what the latest Ez-PAVE results mean for LDL management: it's not just which therapy you use, but how quickly patients reach target LDL-C. #ScientificSessions26 @AHAScience
ahajrnls.org/3Vdj17J
Combo first or statin first? In Ez-PAVE, using a treat-to-target LDL-C strategy, starting with statin-ezetimibe combination therapy or statin monotherapy gave similar cardiovascular efficacy and safety. #ScientificSessions26 @AHAScience @DrlSj @Aspirinbk
ahajrnls.org/4kCz4X0
The goal of AI in cardiology isn't just detecting more abnormalities. It's preventing strokes, reducing symptoms, and improving quality of life. A new commentary examines what LATENT teaches us about AI-guided AF screening. #ScientificSessions26 ahajrnls.org/4z4dRbW
A new commentary from @kellyarps on what the LATENT trial tells us about AI for who and how to screen ECGs, and what to do with what we find. #ScientificSessions26 @AHAScience
ahajrnls.org/3Uh9pso
In LATENT the latent study: AI-guided monitoring of a baseline ECG modestly increased detection of future atrial arrhythmias, mainly in AI-identified high-risk patients, but did not increase AF/AFL diagnosis or treatment. #ScientficSessions26 @AHAScience
ahajrnls.org/4iuuGYL
Just Published at #ScientificSessions26: Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor versus Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarc...\
Full article: ahajournals.org/doi/10.1161/…
@AHAScience
Authors: @ZMotovska @MarcoGuglielmo @DLBHATTMD